Wedbush Forecasts Lower Earnings for Aprea Therapeutics

Aprea Therapeutics, Inc. (NASDAQ:APRE) – Equities researchers at Wedbush decreased their FY2029 EPS estimates for Aprea Therapeutics in a research report issued to clients and investors on Wednesday, May 14th. Wedbush analyst R. Driscoll now expects that the company will earn $1.98 per share for the year, down from their previous estimate of $2.19. Wedbush has a “Outperform” rating and a $11.00 price target on the stock. The consensus estimate for Aprea Therapeutics’ current full-year earnings is ($2.55) per share.

Aprea Therapeutics (NASDAQ:APRE) last announced its earnings results on Wednesday, May 14th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.01). Aprea Therapeutics had a negative return on equity of 57.86% and a negative net margin of 1,029.50%. The business had revenue of $0.16 million for the quarter.

Aprea Therapeutics Price Performance

Shares of APRE stock opened at $1.86 on Friday. The stock has a market cap of $10.28 million, a P/E ratio of -0.66 and a beta of 1.18. The company has a fifty day moving average price of $1.83 and a two-hundred day moving average price of $2.83. Aprea Therapeutics has a one year low of $1.41 and a one year high of $5.42.

Institutional Trading of Aprea Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Stonepine Capital Management LLC lifted its stake in Aprea Therapeutics by 8.8% in the fourth quarter. Stonepine Capital Management LLC now owns 149,221 shares of the company’s stock valued at $491,000 after acquiring an additional 12,047 shares during the last quarter. BNP Paribas Financial Markets acquired a new stake in Aprea Therapeutics in the fourth quarter valued at $43,000. Landscape Capital Management L.L.C. acquired a new stake in Aprea Therapeutics in the fourth quarter valued at $116,000. Finally, LPL Financial LLC acquired a new stake in Aprea Therapeutics in the fourth quarter valued at $53,000. Institutional investors and hedge funds own 34.19% of the company’s stock.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.